Target intelligence / Profile preview

T cell receptor beta variable 28 (TRBV28)

Target
TRBV28
Molecular classification
Receptor, Immunoglobulin superfamily member, Antigen receptor
01

Overview

T cell receptor beta variable 28 (TRBV28) is a protein coding gene encoding the variable domain of the beta chain of the T cell receptor (TCR), which is critical for antigen recognition in adaptive immunity. The TRBV28 segment forms part of the antigen binding site on αβ T cell receptors, enabling T cells to recognize peptide-MHC complexes displayed by antigen presenting cells. This recognition event triggers intracellular signaling cascades (including LCK, CD3 ITAM phosphorylation, and ZAP70 activation) that result in T cell activation, proliferation, and effector function. The Vβ domain diversity is generated by somatic recombination (V(D)J rearrangement) in the thymus, shaping the mature T cell repertoire for the immune response. TRBV28 is highly relevant in immunology, particularly in engineered receptor/cell therapies for cancer and infection, though no approved drugs are directed specifically at TRBV28. Variability in TRBV usage may have diagnostic value in monitoring T cell responses and repertoire diversity in disease contexts

Other names
TRBV28TCRBV3S1TCRBV28S1V_segment translation productTVB28 protein
02

Mechanism of action

Drugs targeting T cell receptors (including CAR-T constructs) use antigen recognition by Vβ domains to activate T cells against disease-associated peptides via MHC complexes, leading to immune cell cytotoxicity or regulation

03

Biological functions

Peptide antigen bindingSignal transductionImmune responseT cell activation
04

Disease associations

Cancer (e.g., immunotherapy relevant)InfectionAutoimmunity and inflammationOther immune-related disease (where T cell response is implicated)
05

Safety considerations

Potential off-target immune activation (autoimmunity, cytokine release syndrome in engineered TCR/CAR-T therapies)Risk of immunogenicity and loss of self-tolerance when altering TCR specificity
06

Interacting drugs

None directly established; however, T cell receptor engineering and CAR-T therapies target TCR variable regions, including TRBV segments, for experimental therapies
07

Biomarkers

T cell clonality and repertoire assessment (e.g., in cancer, infection, or autoimmune disease, profiling TRBV usage can serve as immunoprofiling marker)No clinically-approved biomarkers exclusive for TRBV28

Beyond the preview

Go deeper on T cell receptor beta variable 28 (TRBV28).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor beta variable 28 (TRBV28).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call